Dr. William Williams reports

BRIACELL EXPANDS PIPELINE TO INCLUDE AN OVARIAN CANCER IMMUNOTHERAPY CANDIDATE, BRIA-OVA+™

Briacell Therapeutics Corp. has made progress in developing Bria-OVA+, its next-generation, personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer.

• Briacell expands push in women's health, building on phase 2 success in advanced metastatic breast cancer;
• Bria-OVA+, Briacell's next-generation personalized immunotherapy candidate for ovarian cancer, is designed with additional immune-stimulating components to support enhanced anti-tumour activity;
• Ovarian cancer remains the deadliest gynecologic cancer with over 12,000 women expected to die from the disease in 2026 in the United States.

"Following the encouraging efficacy and tolerability data from Briacell's phase 2 study in metastatic breast cancer, we are expanding our pipeline to include cell-based immunotherapy candidates for gynecologic cancers beginning with ovarian," stated Dr. William V. Williams, Briacell's president and chief executive officer. "Bria-OVA+ reflects our broader strategy to build on the Bria-OTS+ platform and advance next-generation personalized immunotherapies for difficult-to-treat cancers and become a leader in women's health."

"Ovarian cancer remains the deadliest gynecologic cancer, and patients who do not respond to available therapies continue to face serious unmet medical need," stated Dr. Giuseppe Del Priore, Briacell's chief medical officer, and a key opinion leader in ovarian cancer. "We believe Bria-OVA+ has the potential to provide a differentiated immunotherapeutic approach for ovarian cancer patients with limited treatment options."

Briacell recently reported preclinical data for Bria-BRES+, its next-generation breast cancer immunotherapy candidate derived from the same Bria-OTS+ platform. In a recent AACR poster presentation, Bria-BRES+ demonstrated activation of both adaptive and innate immunity, including naive/resting T cells, dendritic cells and natural killer (NK) cells. Briacell believes this multipronged immune activation supports the potential of the Bria-OTS+ platform to generate anti-tumour immune responses and may help inform the development of Bria-OVA+ for ovarian cancer.

Briacell has licensed ovarian cancer cell-lines from American Type Culture Collection (ATCC) and has commenced development activities to support production of Bria-OVA+ for potential clinical use.

Ovarian cancer facts

According to National Cancer Institute, an estimated 21,010 women in the United States will be diagnosed with ovarian cancer and approximately 12,450 will die from the disease in 2026. Ovarian cancer remains the deadliest gynecologic cancer. It is inherited or acquired abnormal BRCA gene. Treatments include surgery to remove the tumour/s, platinum-based chemotherapy, Elahere, a folate receptor alpha-(FRalpha)-directed antibody and microtubule inhibitor conjugate, and Lynparza, a poly (ADP-ribose) polymerase inhibitor, also referred to as a PARP inhibitor. However, many patients do not respond to these treatments and are often associated with harsh side effects.

About Briacell Therapeutics Corp.

Briacell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer.

We seek Safe Harbor.